Joinn Laboratories(China)Co (603127) Fair Value & Analysis
Healthcare · CN · Market cap 38.1B CNY
Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Strengths
Risks
Fair value as of: Aug 13, 2026
From 23 valuation models · updated 11 days ago
Share price +2.5% over the past month.
A solid business, but trading 403% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (¥10.04). The favourable scenario is already priced in.
- Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ¥12.46 – ¥87.11 · fair‑value band ¥7.24 – ¥10.04 · the ¥46.39 price screens above the ¥9.22 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Joinn Laboratories(China)Co (603127) currently trades at ¥46.39, while our model-based Fair Value estimate is ¥9.22, implying the stock looks roughly 80.1% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Joinn Laboratories(China)Co generated revenue of 1.7B CNY at a net margin of 29.4%. Revenue grew 10.0% year over year. It earns a return on equity of 5.9%. The balance sheet holds a net cash position of 904M CNY. Fundamentals as of Aug 13, 2026
Our scenario range runs from ¥7.24 (bear case) to ¥10.04 (bull case); at ¥46.39, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 151% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside, at -80%, 603127 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: Growth Earnings (¥13.89) versus Dividend Discount (¥0.5700). Highest evidence: Growth DCF (80).
Notify me when 603127 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 60 · Market factors (momentum, volatility) 67
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models.
Full company description
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics DMPK studies, and pharmacology and efficacy studies. Its Clinical Trial and Related Services segment provide clinical contract research organization services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment engages in the design, production, breeding, and sale of research models, including non-human primates and rodents. The company also offers cell-based assay (CBA) services. In addition, it offers drug quality research and testing services for protein drugs, vaccines, gene and cell therapy products, and provides customized solutions for early-stage drug discovery, screening, and mechanism research. Joinn Laboratories(China)Co.,Ltd. was incorporated in 1995 and is headquartered in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Joinn Laboratories(China)Co reported revenue of ¥1.7B in FY2025 versus ¥1.5B in FY2021, a compound +2.2%/yr. Reported net income was ¥298M in FY2025, compounding −14.5%/yr from FY2021.
of which total revenue +32.3 pp · buybacks/dilution −6.8 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
603127 screens 80% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 140 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $603.01 | $308.19 | -49% |
| Danaher Corporation DHR | $205.79 | $103.88 | -50% |
| WuXi AppTec Co 2359 | HK$198.90 | HK$157.39 | -21% |
| Lonza Group LONN | CHF 566.20 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $570.58 | $255.77 | -55% |
| Agilent Technologies, Inc A | $148.24 | $61.53 | -58% |
| Waters Corporation WAT | $416.15 | $121.96 | -71% |
| IQVIA Holdings IQV | $236.66 | $132.17 | -44% |
| Illumina, Inc ILMN | $219.40 | $95.51 | -56% |
| Mettler-Toledo International Inc MTD | $1,419 | $615.78 | -57% |
Compare Joinn Laboratories(China)Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Joinn Laboratories(China)Co (603127) overvalued or undervalued?
What is the fair value of 603127?
What is the quality score of 603127?
What is the revenue of Joinn Laboratories(China)Co (603127)?
What is the net profit margin of 603127?
Does Joinn Laboratories(China)Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Joinn Laboratories(China)Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.